Navigation Links
Unique study focuses on combined treatment approach for locally advanced pancreatic cancer
Date:7/22/2014

LOS ANGELES (July 21, 2014) Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.

Locally advanced pancreatic cancer has the lowest survival rate of any solid tumor, with a cumulative five-year survival rate of only 4 percent for all stages of disease. Surgery is rarely an option for patients because tumors often involve vital blood vessels. Chemotherapy and radiotherapy given concurrently remain the mainstay treatment, yet to-date, no treatment has had a significant impact on improving outcomes.

"To move the needle forward toward prolonged survival and better treatment outcomes, our research team created a combined investigational regimen for patients with locally advanced pancreatic cancer," said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive Cancer Institute. "Coupled with this research treatment, we are also looking to identify patient biomarkers, or molecular signatures, that may provide clues to how, and why, some patients respond better than others."

Tuli was the first author of a pre-clinical study recently published in the journal Translational Oncology. Using animal models, the study evaluated a novel treatment for pancreatic cancer that combines radiation, chemotherapy and treatment with a specific drug that can inhibit the repair of cancer cells damaged by chemotherapy and radiation. Successful research findings led to a clinical trial now enrolling eligible patients.

Many standard cancer treatments for pancreatic cancer, including chemotherapy and radiation therapy, kill tumors by damaging their DNA. When such DNA damage occurs, proteins known as PARPs move to the site of damage and begin to mend these broken strands of DNA, allowing cancerous cells and tumors to recover, grow and proliferate, thereby escaping the effects of treatment.

With this knowledge, researchers combined radiation with a drug to prevent PARP from repairing cancerous cells. When the treatment was given to laboratory mice, the combination resulted in prolonged survival.

"Based on this research, we are now conducting a first-in-human study combining the PARP inhibitor with radiation and chemotherapy in patients with locally advanced pancreatic cancer, with an ultimate goal of improving survival rates and treatment outcomes," said Tuli.

The investigational treatment regimen also could prove beneficial to patients with other forms of cancer. Recent research findings suggest PARP could be beneficial for patients who carry either or both the BRCA1 or BRCA2 mutations. "Normal" BRCA genes help suppress tumor formation and repair damaged DNA; the mutated genes' protective mechanisms are compromised, leading to genetic defects that result in cancer. But the "defective" repair capability is a process that may be exploited by treatments, such as PARP inhibition, which further impairs the ability of tumors to repair their own DNA after insult with radiation.

In addition to adding a novel PARP inhibitor to the regimen, investigators are seeking to identify other markers related to DNA damage that could provide a molecular signature, or biomarker, to forecast how a patients' tumor would respond to treatment and help guide personalized treatment options in the near future.

"Identifying individual biomarkers to better understand how a patient may respond to treatment is an essential step toward personalizing medicine for every individual," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and Phase One Foundation Chair. "It is the goal of our cancer institute to combine the most advanced patient-centered clinical care with innovative research that expands treatment options and improves outcomes. This is especially true in pancreatic cancer, which has been long known as a challenging disease to fight."


'/>"/>

Contact: Cara Martinez
cara.martinez@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Unique Collection of Wedding Guest Dresses Released By Stwd.co.uk
2. Unique Quinceanera Dresses For 2014 Offered By MyDressCity.com
3. Urban Aboriginal people face unique health challenges
4. Growth hormone defect may protect against diabetes, cancer in unique ecuador population
5. Bisexual men face unique challenges to their sexual health
6. Understanding the unique nature of childrens bodies and brains
7. Tumors light up with new, unique imaging system using scorpion venom protein and a laser
8. Tracing unique cells with mathematics
9. SpeedRFP Use Grows 70 Percent in 2013, With Nearly 50,000 Unique Event RFPs Submitted During the Year
10. MedMasters Creates a Unique Niche in the Health Care Industry
11. Soon to Be Published: New, Unique Guide for Plastic Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
(Date:3/23/2017)... ... 23, 2017 , ... Vortex Biosciences, provider of circulating tumor ... circulating tumor cells using microfluidic western blotting” in Nature Communications on March 23rd. ... to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that identifying savings ... Healthcare facilities across the country are always forced to focus on costs ... across the country, an efficient and quick way to estimate savings potential within ...
(Date:3/22/2017)... ... 2017 , ... Influence Health, the healthcare industry’s ... enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a 4:1 return ... a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, Virginia, partnered ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 Serve You Rx Vermont, LLC, a wholly ... You), based in Milwaukee, Wisconsin , has ... in Middlebury, Vermont , from Pharmacy Health ... so it was perfect timing for this opportunity to present ... Serve You. "Like us, NEMOP has a high-touch service model, ...
(Date:3/22/2017)... Research and Markets has announced the addition of ... Pipeline Insight 2022" drug pipelines to their offering. ... Global ... report gives comprehensive insight on clinical and non-clinical aspects involved ... as main streamline drugs in the immunotherapy treatment. Report helps ...
(Date:3/22/2017)... Piramal Pharma Solutions (PPS), a ... special event to introduce the new and expanded manufacturing ... . The inaugural event was attended by Governor ... and Piramal Pharma Solutions CEO, Vivek Sharma ... ...
Breaking Medicine Technology: